Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease

Jian-wei Chen, Shu-qin Xie Department of Nephrology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China Objective: Depressive and anxiety symptoms could affect the quality of life and prognostic outcomes in chronic kidney disease (CKD) patients, but only a few studies...

Full description

Bibliographic Details
Main Authors:	Chen JW, Xie SQ
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-02-01
Series:	Neuropsychiatric Disease and Treatment
Subjects:	chronic kidney disease CKD paroxetine agomelatine
Online Access:	https://www.dovepress.com/agomelatine-versus-paroxetine-in-treating-depressive-and-anxiety-sympt-peer-reviewed-article-NDT

Similar Items

Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine
by: Dan J. Stein
Published: (2023-04-01)

Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial
by: Che T, et al.
Published: (2018-06-01)

Comparing the effect of agomelatine and sertraline in treating patients with major depression disorder
by: Afshin Ahmadvand, et al.
Published: (2023-09-01)

AGOMELATINE IN THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: N. Yu. Shimohina, et al.
Published: (2017-03-01)

Comparative Analysis between Controlled Release Paroxetine and Extended-Release Venlafaxine for Treatment of Depression
by: Vijay Kaul, et al.
Published: (2022-06-01)

Agomelatine – pharmacological properties and use in psychiatric practice
by: Marcin Siwek, et al.
Published: (2019-06-01)

Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder
by: Juan Huang, et al.
Published: (2023-04-01)

No interaction between plasma IL-6 and MHPG in major depression treated with paroxetine
by: Reiji Yoshimura, et al.
Published: (2022-09-01)

Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE
by: Medvedev VE
Published: (2017-04-01)

The effects of agomelatine in cisplatin-induced toxicity on the kidney and liver tissues: In vivo study
by: Fatma Nihan Cankara, et al.
Published: (2023-01-01)

Paroxetine in the Treatment of Post Traumatic Stress Disorder: Our Experiences
by: Abdulah Kučukalić, et al.
Published: (2008-02-01)

Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder
by: Shek Ming Leung
Published: (2021-08-01)

Paroxetine-induced galactorrhea
by: S. Petrykiv, et al.
Published: (2022-06-01)

Differentiated approach and indications for optimization of agomelatine therapy for endogenous depression
by: L. I. Abramova, et al.
Published: (2019-06-01)

Comparing the Effectiveness of Paroxetine, Attention Modification Program and Combination of both on Improving Social Anxiety Symptoms
by: Hosein Khedmatgozar, et al.
Published: (2012-08-01)

Acute angle closure glaucoma induced by selective serotonin reuptake inhibitor, and reversed by agomelatine
by: Mehmet Emin Demirkol, et al.
Published: (2019-12-01)

Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm
by: Liliana Civalleri, et al.
Published: (2012-09-01)

UV SPECTROPHOTOMETRIC METHOD FOR QUANTITATIVE DETERMINATION OF AGOMELATINE IN COATED TABLETS
by: Fábio de Souza Barbosa, et al.
Published: (2017-12-01)

Novel Conformationally Constrained Analogues of Agomelatine as New Melatoninergic Ligands
by: Marouan Rami, et al.
Published: (2012-12-01)

Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells
by: Yaprak Donmez Cakil, et al.
Published: (2023-01-01)

Suspected Agomelatine-induced restless legs syndrome: a case report
by: Mustafa Abdul Karim, et al.
Published: (2021-04-01)

Efficacy and safety of agomelatine and SSRIs in the treatment of depressive disorder： a network Meta-analysis
by: Guo Huihui, et al.
Published: (2022-06-01)

Adherence to antidepressant therapy: clinical experience on the example of agomelatine
by: N. N. Petrova
Published: (2022-08-01)

Pharmacokinetics of Paroxetine Tablets in healthy Arabic Subjects
by: Jaafar Jaber Ibraheem Al-Tamimi
Published: (2016-06-01)

A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms
by: David PS, et al.
Published: (2022-03-01)

Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects
by: Fang Tang, et al.
Published: (2016-01-01)

Comparison of the effects of sertraline and agomelatine on sleep quality, sexual functioning and metabolic parameters in patients with major depressive disorder
by: Anıl Talas, et al.
Published: (2019-07-01)

Paroxetine prevented the down-regulation of astrocytic L-Glu transporters in neuroinflammation
by: Koki Fujimori, et al.
Published: (2015-01-01)

Paroxetine—Overview of the Molecular Mechanisms of Action
by: Magdalena Kowalska, et al.
Published: (2021-02-01)

Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model
by: Ahmet Yardimci, et al.
Published: (2021-06-01)

Observational multicenter study of efficacy of paroxetine film-coated tablet in the treatment of anxiety disorder
by: Alma Džubur Kulenović, et al.
Published: (2018-08-01)

Approaches to therapy for depressions in neurology: prospects for the use of agomelatine
by: D. V. Romanov, et al.
Published: (2018-12-01)

First Episode Mania Probably Associated with Discontinuation of Paroxetine Treatment
by: Birmay Cam
Published: (2015-03-01)

Paroxetine Induced Akathisia: Necessity for Rational Use
by: Maryam Mousavi, et al.
Published: (2019-07-01)

Alpha oscillations predict paroxetine response to low sexual desire in depression
by: Mehmet Kemal Arıkan, et al.
Published: (2021-12-01)

The efficacy and tolerability of paroxetine (adepress), an antidepressant from a group of selective serotonin reuptake inhibitors, in psychoautonomic syndrome within anxiety-depressive disorders
by: T G Voznesenskaya, et al.
Published: (2012-06-01)

Treatment of mixed anxiety and depressive disorder: results from a observational study of the efficacy and tolerability of agomelatine
by: D. S. Petelin, et al.
Published: (2021-12-01)

Optimization and improvement of the synthesis method of agomelatine
by: Lei LIU, et al.
Published: (2018-02-01)

Agomelatine Changed the Expression and Methylation Status of Inflammatory Genes in Blood and Brain Structures of Male Wistar Rats after Chronic Mild Stress Procedure
by: Katarzyna Bialek, et al.
Published: (2022-08-01)

Agomelatine Attenuates Isoflurane-Induced Inflammation and Damage in Brain Endothelial Cells
by: Cheng F, et al.
Published: (2020-12-01)